Novel phosphodiesterase-5 (PDE5) inhibitors in the alleviation of erectile dysfunction due to diabetes and ageing-induced oxidative stress.

Article Details

Citation

Copy to clipboard

Gur S, Sikka SC, Hellstrom WJ

Novel phosphodiesterase-5 (PDE5) inhibitors in the alleviation of erectile dysfunction due to diabetes and ageing-induced oxidative stress.

Expert Opin Investig Drugs. 2008 Jun;17(6):855-64. doi: 10.1517/13543784.17.6.855 .

PubMed ID

18491987 [ View in PubMed

]

Abstract

BACKGROUND: Diabetes and ageing are associated with erectile dysfunction (ED). Under these conditions, increased oxidative stress produces superoxide ions, which in turn suppresses the nitric oxide-cyclic guanosine monophosphate pathway. The phophodiesterase-5 (PDE5) inhibitors still remain ineffective in 15 - 57% of impotent men. OBJECTIVE: To identify the efficacy of conventional and novel PDE5 inhibitors on oxidative stress involved in diabetes and ageing. METHODS: An electronic search of the literature was conducted to review published information relating diabetes and ageing to ED and to cover late-stage developments of novel PDE5 inhibitors. RESULTS/CONCLUSION: Safe and more efficacious alternatives that can modulate PDE5 levels in ED regarding oxidative stress conditions are needed. Included in this review are updates on the new PDE5 inhibitors avanafil, udenafil, SLx-2101, and mirodenafil.

DrugBank Data that Cites this Article

Drugs

Avanafil

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Udenafil	cGMP-specific 3',5'-cyclic phosphodiesterase	Protein	Humans	Yes	Inhibitor	Details